Dimerix secures new asset for US$5M
Share
· Dimerix (ASX:DXB) acquired the Phase 2-ready acute kidney injury candidate DMX-652 from Mission Therapeutics for US$5 million upfront.
· The transaction involves potential milestone payments exceeding US$280 million alongside tiered royalties.
· The company stated that the purchase aims to expand its clinical pipeline across the kidney disease continuum.
Biopharmaceutical firm Dimerix (ASX:DXB) acquired a Phase 2-ready acute kidney injury candidate named DMX-652 for US$5 million upfront on July 17.
This acquisition shifts the business away from being a single-asset company centred entirely on its lead drug DMX-200.
"This acquisition broadens our clinical pipeline into complementary indications with significant unmet medical need," said Dimerix CEO Dr Nina Webster.
The agreement includes potential development, regulatory, and sales milestones exceeding US$280 million plus tiered royalties, while a newly secured United States patent extends protection for the compound class to April 11, 2043.
Following the announcement, the Dimerix share price was up at $0.24.
The company continues to advance its flagship candidate DMX-200 through its ongoing Phase 3 focal segmental glomerulosclerosis trial.
Management previously completed adult recruitment for that primary study in December 2025 across 219 clinical sites in 21 countries.
